Incyte Corp.
Sector: Services
Industry: Business Services
60.85
1.87
(3.17%)
Volume:
2,072,024
52 week range:
53.56 - 83.95
Market Cap:
11.779B
Company Description:
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD) It also develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.